ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,306.04
0.02%
US Tech 100
18,375.20
0.31%
다우존스 지수
38,852.86
-0.55%
Bitcoin
68,538.57
0.36%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Verve Therapeutics Inc (VERV)

  7. Verve Therapeutics Inc (VERV) 뉴스

VERV

Verve Therapeutics (VERV)

Verve Therapeutics Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:VERV
일자시간출처헤드라인심볼기업
2024/05/0820:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VERVVerve Therapeutics Inc
2024/05/0820:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VERVVerve Therapeutics Inc
2024/05/0820:00GlobeNewswire Inc.Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial ResultsNASDAQ:VERVVerve Therapeutics Inc
2024/05/0720:00GlobeNewswire Inc.Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102NASDAQ:VERVVerve Therapeutics Inc
2024/05/0405:01GlobeNewswire Inc.Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VERVVerve Therapeutics Inc
2024/04/0220:00GlobeNewswire Inc.Verve Therapeutics Announces Updates on its PCSK9 ProgramNASDAQ:VERVVerve Therapeutics Inc
2024/03/2905:51GlobeNewswire Inc.Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VERVVerve Therapeutics Inc
2024/03/0206:01GlobeNewswire Inc.Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VERVVerve Therapeutics Inc
2024/02/2722:32Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VERVVerve Therapeutics Inc
2024/02/2722:00Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VERVVerve Therapeutics Inc
2024/02/2721:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VERVVerve Therapeutics Inc
2024/02/2721:30GlobeNewswire Inc.Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:VERVVerve Therapeutics Inc
2024/02/1706:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VERVVerve Therapeutics Inc
2024/02/1706:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VERVVerve Therapeutics Inc
2024/02/1706:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VERVVerve Therapeutics Inc
2024/02/0120:30GlobeNewswire Inc.Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:VERVVerve Therapeutics Inc
2024/01/0220:30GlobeNewswire Inc.Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:VERVVerve Therapeutics Inc
2023/12/0206:00GlobeNewswire Inc.Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private PlacementNASDAQ:VERVVerve Therapeutics Inc
2023/11/3006:54Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VERVVerve Therapeutics Inc
2023/11/3006:47Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VERVVerve Therapeutics Inc
2023/11/2920:47Dow Jones NewsVerve Therapeutics Shares Tumble Premarket After Stock SalesNASDAQ:VERVVerve Therapeutics Inc
2023/11/2912:37GlobeNewswire Inc.Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private PlacementNASDAQ:VERVVerve Therapeutics Inc
2023/11/2906:25Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VERVVerve Therapeutics Inc
2023/11/2906:01GlobeNewswire Inc.Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private PlacementNASDAQ:VERVVerve Therapeutics Inc
2023/11/1320:34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VERVVerve Therapeutics Inc
2023/11/1305:30GlobeNewswire Inc.Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial HypercholesterolemiaNASDAQ:VERVVerve Therapeutics Inc
2023/11/0721:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VERVVerve Therapeutics Inc
2023/11/0721:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VERVVerve Therapeutics Inc
2023/11/0720:30GlobeNewswire Inc.Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial ResultsNASDAQ:VERVVerve Therapeutics Inc
2023/10/3119:59Dow Jones NewsBeam Therapeutics to Sell Rights in Verve Licensing Deal to Lilly for $250 Million UpfrontNASDAQ:VERVVerve Therapeutics Inc
 검색 관련기사 보기:NASDAQ:VERV

최근 히스토리

USOTC
RHHBY
Roche (QX)
USOTC
BNPQY
BNP Paribas (QX)
NYSE
JPM
JP Morgan Chase
NYSE
AXP
American Express
NASDAQ
AMZN
Amazon.com
AMEX
XLV
Health Care Select Sector
CCOM
US500
US 500
NYSE
KO
Coca Cola
NYSE
BAC
Bank of America
AMEX
XLF
Financial Select Sector
CCOM
US30
US 30
NASDAQ
AAPL
Apple
USOTC
ADDYY
Adidas (QX)
NYSE
DIS
Walt Disney
PM
XAUUSD
Gold vs US Dollar
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유